Application of G-CSF in high-leukocyte acute myeloid leukemia is a poor prognostic factor
Ping Weng,
Shu Yang,
Shujuan Xu,
Shuxia Zhang,
Yong Wu,
Yuanzhong Chen
Affiliations
Ping Weng
Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, People’s Republic of China
Shu Yang
Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, People’s Republic of China
Shujuan Xu
Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, People’s Republic of China
Shuxia Zhang
Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, People’s Republic of China
Yong Wu
Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, People’s Republic of China
Yuanzhong Chen
Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, People’s Republic of China
ABSTRACTObjective To analyze the effect of granulocyte colony-stimulating factor (G-CSF) on outcomes in patients with acute myeloid leukemia (AML).Methods A total of 526 patients with AML in the Haematology Department were enrolled. They were divided into a G-CSF treatment group and a no G-CSF group according to whether G-CSF was administered in the induction chemotherapy period, with 355 cases in the G-CSF group and 171 cases in the no G-CSF group. Cox regression analysis and Kaplan-Meier curve analysis were used to analyze the effect of G-CSF on the first complete remission (CR1) phase and overall survival (OS). In addition, further analysis was performed based on an initial white blood cell count of 50 * 10^9/L.Results The application of G-CSF significantly shortened the CR1 phase and OS in patients with high leukocytes.Conclusions G/GM-CSF should be used with caution in patients with AML, especially those with high leukocytes.
